Prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants in combination w/ ciclosporin for microemulsion & corticosteroids.
Not to be used in patients w/ hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase eg, Lesch-Nyhan & Kelley-Seegmiller syndrome; & patients w/ galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Increased risk of developing lymphomas & other malignancies particularly of the skin. Over-suppression of the immune system w/ increased susceptibility to infections & sepsis. Viral reactivation in patients infected w/ HBV or HCV; monitor patients infected w/ hepatitis B or C for clinical & lab signs of active HBV or HCV infection. Risk of progressive multifocal leukoencephalopathy & pure red cell aplasia. Reports of hypogammaglobulinaemia & bronchiectasis when combined w/ other immunosuppressants. Patients w/ active serious digestive system disease. Report any sign of bone marrow depression. Perform complete blood counts on a regular basis. Concomitant use of drugs that interfere w/ enterohepatic circulation eg, cholestyramine or activated charcoal. Concomitant use w/ azathioprine; induction therapies eg, anti-T lymphocyte globulin or basiliximab. Avoid use of live attenuated vaccines. Abstinence or highly effective contraception is recommended during treatment. Men should not donate semen during therapy or at least 90 days after discontinuation. Patient should not donate blood during therapy or at least 6 wk after discontinuation. Childn.
Sign Out
